0H8T.LSE Aclaris Therapeutics, Inc.
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -66.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 0H8T.LSE undervalued?
Graham numberThe Graham number of Aclaris Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aclaris Therapeutics, Inc. fundamental analysis
No fundamental analysis for Aclaris Therapeutics, Inc. yet.
Aclaris Therapeutics, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pul…
Full company profileAclaris Therapeutics, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Aclaris Therapeutics, Inc. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 1.68M | 6.15M | 4.23M | 6.48M | 6.76M | 29.8M | 31.2M | 18.7M | 7.83M | 7.25M |
| Gross Profit | -120K | 476K | 1.82M | 172K | 1.35M | 2.05M | 17.8M | -85.2M | 3.46M | 542K | 768K |
| Operating Income | -44.6M | -71.8M | -83.5M | -90.8M | -48.5M | -65.4M | -85.2M | -97.4M | -49.8M | -73.9M | -92.3M |
| EBITDA | -48.2M | -71.4M | -80.8M | -112M | -50.0M | -89.9M | -86.1M | -88.0M | -131M | -73.4M | -91.8M |
| Net Income | -48.1M | -68.5M | -133M | -161M | -51.0M | -90.9M | -86.9M | -88.5M | -132M | -64.9M | -82.7M |
| EPS | -2.25 | -2.44 | -4.03 | -3.90 | -1.20 | -1.60 | -1.33 | -1.27 | -1.71 | -0.53 | -0.58 |
| Balance Sheet | |||||||||||
| Total Assets | 176M | 246M | 276M | 98.3M | 70.8M | 251M | 258M | 200M | 220M | 160M | 180M |
| Total Liabilities | 6.60M | 20.4M | 60.4M | 28.4M | 33.1M | 53.9M | 60.3M | 42.4M | 64.8M | 57.4M | 55.1M |
| Shareholders' Equity | 169M | 225M | 215M | 69.9M | 37.7M | 197M | 198M | 157M | 156M | 103M | 125M |
| Cash & Short-term Investments | 137M | 194M | 168M | 75.0M | 54.1M | 191M | 218M | 119M | 114M | 90.8M | 91.6M |
| Total Debt | - | - | 30.1M | 4.21M | 14.2M | 2.89M | 3.82M | 3.50M | 2.60M | 3.68M | 1.85M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -34.6M | -54.7M | -101M | -96.4M | -38.6M | -52.1M | -67.6M | -78.3M | -20.1M | -47.1M | -76.0M |
| Capital Expenditure | 232K | 1.24M | 68.5M | 1.61M | 453K | 308K | 605K | 1.31M | 121K | 111K | 142K |
| Free Cash Flow | -34.8M | -55.9M | -169M | -98.1M | -39.1M | -52.4M | -68.2M | -79.6M | -20.2M | -47.2M | -76.1M |
| Ratios | |||||||||||
| ROE | -28.4% | -30.4% | -61.7% | -230.8% | -135.5% | -46.0% | -44.0% | -56.3% | -84.9% | -63.0% | -66.3% |
| ROA | -27.3% | -27.9% | -48.2% | -164.1% | -72.1% | -36.2% | -33.7% | -44.3% | -59.9% | -40.5% | -46.0% |
| Net Profit Margin | - | -4,071.5% | -2,158.0% | -3,817.2% | -787.0% | -1,344.0% | -292.1% | -283.1% | -705.5% | -829.6% | -1,140.1% |
| Debt to Equity | - | - | 0.14x | 0.06x | 0.38x | 0.01x | 0.02x | 0.02x | 0.02x | 0.04x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Aclaris Therapeutics, Inc. dividends
Aclaris Therapeutics, Inc. has not paid dividends in the last 9 fiscal years.
Who owns Aclaris Therapeutics, Inc.
- Insiders 2.18%
- Institutions 84.38%
- Public & others 13.44%
- Free float 103M
Aclaris Therapeutics, Inc. company profile
- Company name
- Aclaris Therapeutics, Inc.
- Ticker
- 0H8T.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 69
- Fiscal year end
- December
- Address
- 701 Lee Road, Wayne, PA, United States, 19087
- Phone
- 484 324 7933
- Website
- aclaristx.com
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Aclaris Therapeutics, Inc. management
10- Dr. Neal S. Walker D.O., M.D.Co-Founder, CEO & Chairman · born 1970
- Dr. Hugh M. Davis Ph.D.President, COO & Director · born 1960
- Mr. Kevin BalthaserChief Financial Officer · born 1987
- Mr. James LoeropChief Business Officer · born 1965
- Dr. Roland Kolbeck Ph.D.Chief Scientific Officer · born 1964
- Mr. William C. RobertsSenior Vice President of Corporate Communications & Investor Relations · born 1969
- Mr. Matthew Rothman J.D.General Counsel & Corporate Secretary
- Mr. Steve TuckerExecutive Vice President of Project Leadership
- Dr. Jesse W. Hall M.D.Chief Medical Officer · born 1974
- Ms. Nina Samra M.S.Senior Vice President of Clinical Operations